Provided by Tiger Trade Technology Pte. Ltd.

IGC Pharma

0.3053
+0.00531.77%
Post-market: 0.3001-0.0052-1.70%19:59 EST
Volume:1.30M
Turnover:395.09K
Market Cap:28.35M
PE:-3.92
High:0.3164
Open:0.3163
Low:0.2950
Close:0.3000
52wk High:0.4985
52wk Low:0.2525
Shares:92.87M
Float Shares:83.13M
Volume Ratio:0.72
T/O Rate:1.56%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0780
EPS(LYR):-0.0931
ROE:-83.34%
ROA:-50.31%
PB:3.50
PE(LYR):-3.28

Loading ...

IGC Pharma Secures U.S. Patent for Microdose Cannabinoid Treatment of Stuttering and Tourette's Syndrome

Reuters
·
Dec 19

IGC Pharma Inc - Increases Authorized Common Stock to 600 Mln Shares - SEC Filing

THOMSON REUTERS
·
Dec 16

IGC Pharma Quadruples Authorized Common Shares to 600 Million

Reuters
·
Dec 16

Ascendiant Capital Markets Raises IGC Pharma Price Target to $4.75

Reuters
·
Dec 10

IGC Pharma Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 10

IGC Pharma Reaches 65% Enrollment in Phase 2 CALMA Trial for Alzheimer’s Agitation

Reuters
·
Dec 09

Press Release: NeoVolta Enters into Definitive Agreements Led by Infinite Grid Capital to Advance 2 GWh U.S. Battery Energy Storage System Manufacturing Initiative

Dow Jones
·
Nov 24

IGC Pharma Reports Progress Amid Financial Losses

TIPRANKS
·
Nov 18

IGC Pharma expects ‘continued strong momentum’ into 2H26

TIPRANKS
·
Nov 17

IGC Pharma Q2 EPS $(0.02), Inline, Sales $191.000K Miss $325.000K Estimate

Benzinga
·
Nov 17

IGC Pharma Sells Non-Core Facility for $2.7 Million

Reuters
·
Nov 17

IGC Pharma files to sell 978,235 shares of common stock for holders

TIPRANKS
·
Nov 17

IGC Pharma Reports Lower Revenue Amid Shift to Alzheimer’s Drug Development

Reuters
·
Nov 15

IGC Pharma Sells Vancouver Assets to Wellness Essentials

TIPRANKS
·
Nov 14

IGC Pharma Granted U.S. Patent for Novel Alzheimer's Drug Composition Targeting CNS Disorders

Reuters
·
Nov 13

IGC Pharma expands Phase 2 CALMA trial to University of South Florida

TIPRANKS
·
Oct 14

IGC Pharma Inc. Held Annual Meeting of Stockholders

Reuters
·
Oct 14

IGC Pharma announces in-vitro preclinical data for IGC-1C

TIPRANKS
·
Oct 07

IGC Pharma Announces Promising Preclinical Results for IGC-1C, a Novel Drug Candidate Targeting Tau Protein in Alzheimer’s Disease

Reuters
·
Oct 07

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

GlobeNewswire
·
Oct 06